anagliptin
Sign in to saveAnagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".
Research
127 papers- Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis.Medicine · 2024
- Anagliptin stimulates osteoblastic cell differentiation and mineralization.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020
- Anagliptin prevents lipopolysaccharide (LPS)- induced inflammation and activation of macrophages.International immunopharmacology · 2022
- Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability.Diabetes, metabolic syndrome and obesity : targets and therapy · 2015
- Anagliptin promotes apoptosis in mouse colon carcinoma cells via MCT-4/lactate-mediated intracellular acidosis.Experimental and therapeutic medicine · 2022
via PubMed
~1 min read
Encyclopedic overview
2 sectionsContents
- Research
- References
Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".
== Research == A systematic review and meta-analysis of anagliptin, published in 2024, found that it is effective in lowering blood glucose in people with type2 diabetes and that it may lower cholesterol.
Excerpted from Wikipedia’s “anagliptin” article, available under the CC BY-SA 4.0 licence.
Available in 7 languages
via Wikidata sitelinks · CC0